Re-emergence of Meningococcal Carriage on Three-year Follow-up of a Kibbutz Population After Whole-community Chemoprophylaxis
Overview
Microbiology
Affiliations
A long-term study was conducted to determine the rate of re-emergence of throat carriage of meningococci in a semi-closed kibbutz community after the administration of chemoprophylaxis to all its members. Serotype B:4 was selected as marker organism since it was isolated from a fatal case and was the most frequently occurring strain (80%) among serogroup B isolates, which themselves comprised 54% of all meningococci. The carriage rate among Israeli residents (volunteer workers were analyzed separately) before treatment was 6.6% (49/748) overall, with 4.3% group B strains. Three weeks after treatment, in most cases with rifampicin (whereby three persistently positive persons were retreated with minocycline), no meningococci were recovered. Six months later, 1.9% of a population sample aged < or = 30 years were positive, while before treatment and one and three years later, 9.4%, 8.6% and 4.6% respectively were positive in this age group. Serotype B:4 comprised 81.3% of group B strains before prophylaxis, 5.3% after one year, and 28.6% after three years, thus possibly re-establishing itself as the single dominant serotype. The marked suppression of carriage after mass chemoprophylaxis appeared to last at least six months, with the meningococcal population being re-established within a year.
Kenyon C Pathogens. 2020; 9(2).
PMID: 32085650 PMC: 7168587. DOI: 10.3390/pathogens9020134.
Mass chemoprophylaxis for control of outbreaks of meningococcal disease.
McNamara L, MacNeil J, Cohn A, Stephens D Lancet Infect Dis. 2018; 18(9):e272-e281.
PMID: 29858150 PMC: 6599585. DOI: 10.1016/S1473-3099(18)30124-5.
Valinsky L, Jaffe J, Keller N, Block C, Abramson N, Stein-Zamir C Epidemiol Infect. 2015; 144(1):183-8.
PMID: 26113514 PMC: 9507310. DOI: 10.1017/S0950268815001296.